Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields. While its many segments are experiencing pullbacks in the end market, its top growth segment is being driven by solutions to address polyfluoroalkyl substances (PFAS), otherwise known as forever chemicals ...

In this articleAIR-FRAGEBAAALTULSA, Okla. — Parts and labor shortages. Delayed deliveries of new airplanes from Boeing and Airbus. An engine recall. Premature repairs. It's all piling up, and aircraft engine shops around the world are overflowing. As travelers boarded planes in record numbers this summer, airline executives waited anxiously for repairs and overhauls of their engines.The repair and overhaul of engines has swelled from a $31 billion business before the pandemic to $58 billion this year, accor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended July 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For transition period from to Commission File Number: 001-15405 AGILENT TECHNOLOGIES, INC. (Exact Name of registrant as specified in its charter) Delaware 77-0518772 (State or other jurisd ...

Have you assessed how the international operations of Agilent Technologies (A) performed in the quarter ended July 2024? For this scientific instrument maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become es ...

hapabapa Agilent Technologies (NYSE:A) offers instruments, consumables, software and services to life sciences, diagnostics and applied chemical markets. Agilent has made significant efforts in transforming its business towards growth areas including biopharma, polyfluoroalkyl substances (PFAS) testing and advanced materials for semiconductor. I am initiating a ‘Buy’ rating with a one-year target price of $160 per share. Growing Biopharma, PFAS & Advanced Materials Agilent offers workflow solutions for ...

Agilent Technologies (A) has delivered third-quarter fiscal 2024 earnings of $1.32 per share, which beat the Zacks Consensus Estimate by 5.6%. However, the bottom line decreased 8% from the year-ago quarter. Revenues of $1.58 billion beat the Zacks Consensus Estimate of $1.56 billion. The top line declined 5.6% on a reported basis and 4.4% on a core basis from the year-ago quarter. The decline was attributed to broad-based weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and G ...

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%. Adjusted EPS of $1.32 surpassed the street view of $1.26.Agilent said it sees fourth-quarter revenue of $1.641 billion – $1.691 b ...

Agilent Technologies (NYSE:A) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32. This was above the analyst estimate for EPS of $1.26. The company reported revenue of $1.58 billion. This was 1.15% better than the analyst estimate for revenue of $1.56 billion. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings pe ...

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $1.578 billion, a decline of 4.4%, but an improvement of 300 basis points from Q2 [6][18] - Operating margin improved to 27.4%, reflecting the effectiveness of cost-saving measures [6][22] - Earnings per share (EPS) was $1.32, exceeding guidance by $0.04, but down 7.7% year-over-year [6][22] Business Line Data and Key Metrics Changes - Life Sciences and Applied Markets Group (LSAG) reported revenue of $782 million, down 7%, with consumables growing mid-single digits [10][11] - Agilent CrossLab Group (ACG) delivered revenue of $411 million, up mid-single digits, with a record operating margin of 34% [12] - Diagnostics and Genomics Group (DGG) posted revenue of $385 million, representing an 8% decline, with pathology growing mid-single digits [13] Market Data and Key Metrics Changes - The largest market, pharma, declined high-single-digits, with biopharma under pressure but small molecule performing relatively better [9][19] - Europe exceeded expectations, driven by small-molecule pharma and environmental markets, while China saw an 11% decline [10][21] - Environmental & Forensics grew 4%, supported by strong performance in PFAS testing [20] Company Strategy and Development Direction - The company is focused on biopharma, PFAS, and Advanced Materials as key growth vectors [8] - Agilent is investing in its digital ecosystem to enhance customer experience and accelerate value creation [7] - Two acquisitions were announced to strengthen capabilities in biopharma and digital solutions, with a focus on enhancing recurring revenue [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady market improvement and raised guidance for revenue and EPS for the full year [6][24] - The company is adapting its strategy to market trends while maintaining a focus on customer relationships and innovation [8][27] - Management noted that while capital equipment budgets remain constrained, lab activity is improving, particularly in services and consumables [10][21] Other Important Information - The company announced the acquisition of BIOVECTRA, enhancing capabilities in oligonucleotides and CRISPR therapeutics [15] - The acquisition of Sigsense aims to optimize lab operations through AI technology [16] - Agilent's ESG report highlighted a commitment to sustainability, with 40% of instrument revenue coming from certified products [17] Q&A Session Summary Question: Insights on LSAG performance and instrument demand - Management noted strong growth in consumables and services, with stable lab activity, but instrument demand remains challenged [30][31] Question: Trends in Academic & Government market - A decline of 11% was noted, with stable funding in most regions, but a reallocation towards defense in Europe [33][34] Question: NASD performance and future expectations - NASD is expected to see a sequential step-up in Q4, with strong bookings activity indicating a return to growth [36][41] Question: Outlook for China and capital spending - Management is optimistic about mid-term recovery in China, with increased lab activity and services despite current demand constraints [45][47] Question: Margin expectations for 2025 - Continued efficiency improvements are expected, with a commitment to achieving $100 million in cost savings by the end of 2024 [49][50] Question: Instrumentation trends and recovery - Management indicated cautious optimism, with a stable order book and positive customer sentiment, although recovery is expected to be slow [74][75]

For the quarter ended July 2024, Agilent Technologies (A) reported revenue of $1.58 billion, down 5.6% over the same period last year. EPS came in at $1.32, compared to $1.43 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of +0.99%. The company delivered an EPS surprise of +5.60%, with the consensus EPS estimate being $1.25.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...